Navigation Links
Memantine and Alzheimer's disease
Date:1/10/2008

Amsterdam, January 9, 2008 In a study published this month in the Journal of Alzheimer's Disease, researchers from the University of Aberdeen report that the drug memantine, used for the treatment of Alzheimer's disease and praised as "the first and only representative of a new class of Alzheimer drugs" works in fact similar to other existing compounds, and is beneficial only in a narrow concentration range. They further indicate that the complex pharmacological profile of memantine requires careful consideration concerning suitable doses and suitable patient groups, so that the best use can be achieved for patients suffering from Alzheimer's disease.

Dementia is an ever-increasing problem in todays aging societies, with millions of patients and their carers affected worldwide. About one in five people over the age of 80 suffers from Alzheimers disease, the most common type of dementia. There is no cure and little hope is available for treatment, thus leaving the prospect of years or even decades of progressive mental deterioration.

In Alzheimers disease, two systems necessary for the communication of brain cells fail: The stimulatory brain messenger acetylcholine is down-regulated, while over-activation of the messenger glutamate leads to the death of neurones.

The first-generation of compounds aimed to boost the brains acetylcholine levels led to the development of drugs such as Aricept (donepezil) and Excelon (rivastigmine). Attempts to develop drugs that block the action of glutamate by a considerable number of pharmaceutical companies and researchers were not successful for a long time, since these receptors are also required for normal brain function, learning and memory in particular. It was therefore considered a major breakthrough when a drug called memantine was discovered to have beneficial effects in Alzheimers disease, which did not affect the normal function of glutamate signalling, but only the excessive actions leading to cell death. Memantine (trade names: Namenda, Axura, Ebixa) was approved in 2002 by the European Agency for the Evaluation of Medicinal Products and in 2003 by the US FDA (Food and Drug Administration) for the treatment of moderate-to-severe Alzheimers disease. The arrival of this compound was greeted with great expectations since it could potentially be beneficial not only for Alzheimers disease, but also for other brain disorders that involve excess glutamate stimulation, such as trauma and stroke.

In the UK, much debate has centred on the recommendation of drugs which may help Alzheimer patients with day to day tasks. Cost-benefit analysis has led NICE (National Institute for Clinical Excellence (http://guidance.nice.org.uk/TA111/) to issue guidelines limiting the availability of Alzheimer-related drugs to specific patient groups. This decision has been widely criticized by patient representatives and Alzheimer support charities such as the Alzheimers Research Trust.

In the present study, researchers report that memantine has a much more complex pharmacological profile than originally described. It does in fact work rather similar to the originally introduced drugs that affect acetylcholine-related signalling, in addition to weak actions on glutamate, and has negative effects on neuronal communication at high concentrations. At lower concentrations, memantine was able to enhance signalling between neurones of the hippocampus (the main brain area affected in Alzheimers disease) and was indeed able to reverse learning and memory deficits. However, a pharmacological analysis showed that this was not due to its ability to block glutamate signalling, but rather to an additional and more potent action on the acetylcholine system.

Therefore, the investigators data do confirm that memantine shows promising aspects for the treatment of AD, but only in a narrow concentration range. More importantly, its complex pharmacological profile requires careful considerations concerning suitable doses and suitable patient groups, so that the best use can be achieved for patients suffering from Alzheimers disease.

Lead investigator Dr. Bettina Platt, University of Aberdeen, Institute of Medical Sciences, commented, Clearly, the claim that memantines beneficial action is due to the reduction of glutamate signalling needs to be revised. It is highly unlikely that compounds directly targeting glutamate receptors will be successfully introduced into the clinic, since major side-effects must be expected.


'/>"/>

Contact: Astrid Engelen
a.engelen@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
2. Smoking may strongly increase long-term risk of eye disease
3. Pot bellies linked to early signs of cardiovascular disease
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Radiologists encouraged to look beyond cancer for clinically unseen diseases
6. Use of certain lipid measures not more effective in predicting coronary heart disease
7. Role seen for cannabis in helping to alleviate allergic skin disease
8. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
9. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
10. New research shows how chronic stress worsens neurodegenerative disease course
11. A new molecular zip code, and a new drug target for Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... , ... An inventor and manicurist from Greet, S.C., wants to offer people a new way ... maintain clean and healthy feet, so I know the importance of proper foot care," he ... designed the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate ...
(Date:3/30/2017)... ... March 30, 2017 , ... This ... to President Trump expressing their support for an independent Vaccine Safety Commission. Five ... and one medical journalist, will hold a press conference at 9:00 AM ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... In the ... to 300,000 people each year develop other types of metastatic brain tumors(3). Though most ... the brain(3). As efforts focus on finding more effective treatment options, the San ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... St. Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... Often called the "Spice of Life" or "Wonder Spice", it has been used for ... extensive use in the East," says Heshelow, author of " Turmeric: How to Use ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... , March 30, 2017  Purcell Julie & Lefkowitz LLP, ... is investigating a potential breach of fiduciary duty claim involving ... SGYP ). If you are a ... information regarding this investigation, free of charge, please visit us ... ...
(Date:3/29/2017)... March 29, 2017  Bodycad announced today that ... (FDA) 510(k) clearance for its Bodycad Unicompartmental Knee ... personalized orthopaedic restoration. Bodycad is the first Canadian ... reconstruction implant system. Bodycad,s revolutionary ... restoration of the patient,s unique anatomical features and ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global energy-based aesthetic devices market ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
Breaking Medicine Technology: